Note: On 23 November 2017, the Administrative Appeals Tribunal designated N-acetyl cysteine Omeprazole (NACO) as an orphan drug pursuant to an agreement reached between the parties under section 42C of the Administrative Appeals Tribunal Act 1975 (AAT Act). The designation follows the decisions of the Minister's delegate and the Secretary's delegate not to designate NACO as an orphan drug. Pursuant to subsection 43(6) of the AAT Act, the designation takes effect from the date of the decision of the Minister's delegate, being 21 July 2017.
This gene encodes a member of the aldo/keto reductase superfamily , which consists of more than 40 known enzymes and proteins. These enzymes catalyze the conversion of aldehydes and ketones to their corresponding alcohols by utilizing NADH and/or NADPH as cofactors. The enzymes display overlapping but distinct substrate specificity. This enzyme catalyzes the reduction of prostaglandin (PG) D2, PGH2 and phenanthrenequinone (PQ), and the oxidation of 9alpha,11beta-PGF2 to PGD2. It may play an important role in the pathogenesis of allergic diseases such as asthma, and may also have a role in controlling cell growth and/or differentiation. This gene shares high sequence identity with three other gene members and is clustered with those three genes at chromosome 10p15-p14.